Suppliers and packagers for generic pharmaceutical drug: ibrutinib

ibrutinib

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552	NDA	Pharmacyclics LLC	57962-070-28	28 CAPSULE in 1 BOTTLE, PLASTIC (57962-070-28)	2017-12-20
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552	NDA	Pharmacyclics LLC	57962-140-09	90 CAPSULE in 1 BOTTLE, PLASTIC (57962-140-09)	2013-11-13
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552	NDA	Pharmacyclics LLC	57962-140-12	120 CAPSULE in 1 BOTTLE, PLASTIC (57962-140-12)	2013-11-13
Pharmacyclics Llc	IMBRUVICA	ibrutinib	SUSPENSION;ORAL	217003	NDA	Pharmacyclics LLC	57962-007-12	1 BOTTLE, GLASS in 1 CARTON (57962-007-12) / 108 mL in 1 BOTTLE, GLASS	2022-08-24

Ibrutinib Suppliers and Manufacturing Vendors: Who Makes Imbruvica and Other Bruton’s Tyrosine Kinase (BTK) Products

Last updated: July 17, 2026

Ibrutinib supply chains break into (1) active pharmaceutical ingredient (API) sourcing for the BTK inhibitor and (2) finished-dose manufacturing for marketed products (notably Imbruvica). The strongest way to map “suppliers” is by pairing FDA drug-substance and drug-product manufacturing references in regulatory filings with public supplier footprints reported in drug master files (DMFs), contract manufacturing organization (CMO) disclosures, and procurement patterns.

Which companies supply ibrutinib API and contract it for manufacturing?

The ibrutinib API manufacturing landscape is typically split between DMF holders and suppliers used by the branded manufacturer and its contract manufacturers for scale-up and lifecycle changes (analytical updates, polymorph control, crystallization process improvements). For business planning, treat “supplier” as one of three roles: (a) DMF holder or API manufacturer of record, (b) secondary API supplier for launch readiness and redundancy, and (c) CMO that converts API into tablets or capsules under cGMP.

Key i brutinib API supply-chain roles to track

• Drug Substance (API) manufacturer(s) tied to DMFs and/or listed in NDA/ANDA modules.
• Drug Product manufacturer(s) for tablet manufacturing, coating, blending, compression, encapsulation, and packaging.
• Packaging suppliers (bottles, labels, serialized packs) that affect distribution timelines but do not own the API.

Where supplier identification is anchored

• FDA Orange Book entries reflect listed drug products and approved manufacturing sites, which often point to drug-product CMOs rather than API.
• FDA DMF records (where publicly referenced in patent and regulatory histories) tie to API synthesis and quality systems.
• Public CMC and site-change records in FDA submissions identify incremental process changes that can shift supplier lists.

Ibrutinib “suppliers” therefore differ by granularity: API vs. finished dose. Branded Imbruvica manufacturing sites and their contract roles are the cleanest starting point for procurement and regulatory risk analysis, while API supplier names usually require DMF-level mapping.

What finished-dose manufacturers produce Imbruvica (ibrutinib) tablets and capsules?

For ibrutinib, the marketed finished product historically includes oral solid dosage forms (tablets and capsules depending on strength/label evolution). Finished-dose manufacturers are the practical “supplier” counterpart for distribution agreements, clinical bridging, and commercial re-supply.

How to map finished-dose manufacturing suppliers

1. Use the Orange Book for the listed drug to find the approved application (NDA) and manufacturing details.
2. Cross-reference manufacturing site updates in FDA CMC supplements to identify when a CMO gained or lost manufacturing authorization.
3. Track packaging configuration and NDC-level changes, which often coincide with site changes.

Common procurement reality for ibrutinib

• Branded supply is managed via primary CMO(s) plus backup sites to avoid drug shortages.
• Site qualification under cGMP means supplier swaps require comparability data and FDA review or reduced-change pathways depending on the submission type.

Which ibrutinib competitors and generics create additional supplier demand?

Generic and biosimilar-like competition is the key driver of supply diversification in small-molecule oncology. Ibrutinib is a small-molecule and follows ANDA pathways, not biosimilars. The “suppliers” relevant to generics are (a) ANDA API makers and (b) drug-product manufacturers who win batch slots for commercial launch.

Generic supply-chain implications

• API is the gating item for early launch because process development, impurity profiling, and polymorph control are binding to regulatory acceptance.
• Drug-product manufacturing then becomes the critical constraint for tablet/capsule release, stability, and formulation equivalence.

What is the Orange Book status of Imbruvica (ibrutinib) and how does that affect supplier entry?

Orange Book exclusivity and patent status determine when generic suppliers can enter at risk and when they can launch under FDA approval.

Why Orange Book matters for supplier planning

• If major patents block marketing, even a ready CMO and API supplier cannot ship without legal risk.
• If patents expire or are carved out by settlement, supplier onboarding accelerates.

Practical supplier consequence

• Supplier RFPs often run in parallel with Paragraph IV readiness, then pivot to commercial production only after litigation milestones.

When do ibrutinib patents and exclusivity expire, and when can suppliers launch generics?

Launch timing hinges on:

• Patent expiration for key compositions, methods of use, and formulations.
• Regulatory exclusivities (if applicable) and any terminal disclaimers.
• Paragraph IV litigation and settlement-driven carve-outs.

How launch timing flows into supplier decisions

• API suppliers can prepare earlier, but release to market generally cannot occur until the ANDA is approved and market entry risk is cleared.
• CMOs usually ramp production only after approval and stability data packages are accepted or waived.

How strong is the ibrutinib patent estate for supplier entry barriers?

For BTK inhibitors, patent estates frequently cover:

• Core compound and analog claims
• Polymorphs / crystal forms
• Formulation approaches (excipients, coatings, particle size, solid-state parameters)
• Method-of-use indications, often expanded across hematologic malignancies

Supplier impact

• Strong formulation and method patents can force generic suppliers into narrower development paths.
• If formulation claims cover the delivery form, ANDA applicants must design around protected features.

What patent litigation affects ibrutinib generic and supplier ramp-up?

Generic entry for ibrutinib is typically shaped by:

• Paragraph IV filings
• Injunction motions and/or trial schedules
• Settlement agreements that set entry dates or carve-out indications

Why litigation status matters to suppliers

• Even with ANDA readiness, commercial distribution requires legal clearance.
• Settlement can shift which suppliers get manufacturing slots first based on agreed entry scope and launch dates.

How many suppliers exist for ibrutinib API and what are the bottlenecks?

A precise supplier count requires regulator-linked lists of API manufacturers tied to DMFs and/or labeled manufacturers on the Orange Book. Publicly accessible high-confidence counts are not consistently available in a single dataset because:

• DMF names can differ from commercial branding
• APIs may route through trading or relabeling intermediaries
• site approvals change over time

Bottlenecks that consistently constrain ibrutinib supply

• Solid-state control (form, crystallinity, impurity profile)
• Scale-up chemistry and solvent handling
• Analytical method readiness (impurity quant, stability-indicating assays)
• Tablet/capsule manufacturability (compression properties, dissolution control, coating uniformity)

How does ibrutinib supplier landscape differ by region (US/EU/Asia)?

Regulatory markets segment supplier choices because:

• cGMP standards differ in practice across regions even when aligned to ICH
• export documentation, importation licensing, and traceability requirements differ
• local tendering patterns and clinical-use obligations can preselect CMOs

Commercial outcome

• US launches often rely on US-authorized manufacturing sites with documented GMP compliance.
• Europe may leverage authorized local batch release and QP certification workflows.

Which companies are the finished-dose CMOs for ibrutinib tablets/capsules?

Finished-dose CMOs for Imbruvica are identified through approved manufacturing site listings and CMC supplements tied to the NDA. Those site lists are the highest-fidelity method to determine “who manufactures” rather than “who supplies inputs.”

What to extract for procurement

• NDA manufacturing site authorization
• dosage strength coverage per site
• packaging configuration and NDC association
• batch release responsibility (site vs distributor)

What formulations of ibrutinib are protected and how does that affect suppliers?

Ibrutinib formulation protection can include:

• immediate-release solid oral dosage parameters
• coating systems
• excipient selections and ratios affecting dissolution rate
• particle size and solid-state parameters tied to stability and bioavailability

Supplier consequence

Generic formulation acceptance can be blocked by formulation-specific protection or by the need for additional bridging studies.

Key Takeaways

• “Suppliers for ibrutinib” splits into API manufacturers (often DMF-linked) and finished-dose manufacturers for Imbruvica (site-linked via Orange Book and NDA manufacturing authorizations).
• The supplier set you can rely on for commercial planning is best mapped through Orange Book manufacturing sites (drug product) plus DMF-linked API sources (drug substance).
• Patent and litigation status dictates when generic suppliers can move from development to commercial shipping, not when they can synthesize or blend.
• For procurement and regulatory risk, treat supplier onboarding as a site-authorization and comparability exercise, not a simple vendor swap.

FAQs

1. How can I identify the API manufacturer behind an ibrutinib ANDA?
2. Which manufacturing sites are approved for Imbruvica tablets versus capsules?
3. Do ibrutinib formulation patents typically cover excipients, coatings, or only solid-state parameters?
4. How do Paragraph IV settlements affect the earliest generic supplier launch dates for ibrutinib?
5. What quality-system bottlenecks most often delay ibrutinib API or tablet batch release?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA Drug Master Files (DMF) database and public DMF-related references. U.S. Food and Drug Administration.
3. FDA Labels and prescribing information for Imbruvica (ibrutinib). U.S. Food and Drug Administration.